Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2012

01-04-2012 | Article

Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death

Authors: E. Reich, A. Tamary, R. Vogt Sionov, D. Melloul

Published in: Diabetologia | Issue 4/2012

Login to get access

Abstract

Aim/hypothesis

Glucocorticoid hormones (GCs) are widely used to treat a variety of inflammatory and immune diseases. However, their long-term administration is associated with adverse metabolic effects, including glucose intolerance and diabetes. Our objective was to elucidate the mechanisms by which GCs affect beta cell survival with a specific emphasis on the role of the thioredoxin-interacting protein (TXNIP) in beta cell apoptosis.

Methods

Human and mouse islets, together with MIN6 beta cells, were exposed to dexamethasone (Dex) and apoptosis was assessed by measuring the percentage of sub-G1 cells, the appearance of cleaved caspase-3 or by using a TUNEL assay. Dex-upregulated expression of Txnip mRNA was analysed by real-time PCR, and GC-modulated production and modification of proteins were determined by western blotting.

Results

We provide evidence that TXNIP, a negative regulator of the antioxidant thioredoxin (TRX), is strongly induced in beta cells by GCs and that its induction is dependent on p38 mitogen-activated protein kinase (MAPK) activation. TXNIP downregulation by RNA interference, overexpression of the radical scavenger TRX1 or elevation of intracellular cAMP levels attenuated the Dex-mediated apoptosis. Dex-induced Txnip expression and beta cell apoptosis are mediated by the glucocorticoid receptor (GR), as the GR antagonist RU486 fully abolishes these effects.

Conclusions/interpretation

Altogether, our data suggest TXNIP as a novel mediator of GC-induced apoptosis in beta cells and further contribute to our understanding of beta cell death pathways.
Appendix
Available only for authorised users
Literature
1.
Huang W, Glass CK (2010) Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol 30:1542–1549PubMedCrossRef
2.
Saad MJ, Folli F, Kahn JA, Kahn CR (1993) Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065–2072PubMedCrossRef
3.
van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39:81–93PubMedCrossRef
4.
5.
Khan A, Ostenson CG, Berggren PO, Efendic S (1992) Glucocorticoid increases glucose cycling and inhibits insulin release in pancreatic islets of ob/ob mice. Am J Physiol 263:E663–E666PubMed
6.
Delaunay F, Khan A, Cintra A et al (1997) Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 100:2094–2098PubMedCrossRef
7.
Lambillotte C, Gilon P, Henquin JC (1997) Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 99:414–423PubMedCrossRef
8.
Larsson H, Ahren B (1999) Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 42:936–943PubMedCrossRef
9.
Jeong IK, Oh SH, Kim BJ et al (2001) The effects of dexamethasone on insulin release and biosynthesis are dependent on the dose and duration of treatment. Diabetes Res Clin Pract 51:163–171PubMedCrossRef
10.
van Raalte DH, Nofrate V, Bunck MC et al (2010) Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. European J Endocr/European Federation of Endocrine Societies 162:729–735CrossRef
11.
van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M (2011) Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34:412–417PubMedCrossRef
12.
Scharfmann R, Duvillie B, Stetsyuk V, Attali M, Filhoulaud G, Guillemain G (2008) Beta-cell development: the role of intercellular signals. Diabetes Obes Metab 10(Suppl 4):S195–S200CrossRef
13.
Blondeau B, Lesage J, Czernichow P, Dupouy JP, Breant B (2001) Glucocorticoids impair fetal beta-cell development in rats. Am J Physiol 281:E592–E599
14.
Gesina E, Tronche F, Herrera P et al (2004) Dissecting the role of glucocorticoids on pancreas development. Diabetes 53:2322–2329PubMedCrossRef
15.
Goodman PA, Medina-Martinez O, Fernandez-Mejia C (1996) Identification of the human insulin negative regulatory element as a negative glucocorticoid response element. Mol Cell Endocrinol 120:139–146PubMedCrossRef
16.
Sharma S, Jhala US, Johnson T, Ferreri K, Leonard J, Montminy M (1997) Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. Mol Cell Biol 17:2598–2604PubMed
17.
Zawalich WS, Tesz GJ, Yamazaki H, Zawalich KC, Philbrick W (2006) Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets. Metabolism 55:35–42PubMedCrossRef
18.
Ranta F, Avram D, Berchtold S et al (2006) Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 55:1380–1390PubMedCrossRef
19.
Chen KS, DeLuca HF (1994) Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta 1219:26–32PubMed
20.
Nishinaka Y, Masutani H, Nakamura H, Yodoi J (2001) Regulatory roles of thioredoxin in oxidative stress-induced cellular responses. Redox Rep 6:289–295PubMedCrossRef
21.
Chutkow WA, Patwari P, Yoshioka J, Lee RT (2008) Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem 283:2397–2406PubMedCrossRef
22.
Shalev A (2008) Lack of TXNIP protects beta-cells against glucotoxicity. Biochem Soc Trans 36:963–965PubMedCrossRef
23.
Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G (2009) Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 52:636–644PubMedCrossRef
24.
Cha-Molstad H, Saxena G, Chen J, Shalev A (2009) Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells. J Biol Chem 284:16898–16905PubMedCrossRef
25.
Chen J, Hui ST, Couto FM et al (2008) Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 22:3581–3594PubMedCrossRef
26.
Chen J, Fontes G, Saxena G, Poitout V, Shalev A (2010) Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes 59:440–447PubMedCrossRef
27.
Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E (2008) Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res 101:127–248PubMedCrossRef
28.
Kfir-Erenfeld S, Sionov RV, Spokoini R, Cohen O, Yefenof E (2010) Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leuk Lymphoma 51:1968–2005PubMedCrossRef
29.
Chen Z, Lopez-Ramos DA, Yoshihara E et al (2010) Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T cell sensitivity to glucocorticoid during HTLV-I-induced transformation. Leukemia 25:440–448PubMedCrossRef
30.
Eldor R, Yeffet A, Baum K et al (2006) Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci USA 103:5072–5077PubMedCrossRef
31.
Brunstedt J, Nielsen JH (1981) Direct long-term effect of hydrocortisone on insulin and glucagon release from mouse pancreatic islets in tissue culture. Acta Endocrinol 96:498–504PubMed
32.
Wang Z, Rong YP, Malone MH, Davis MC, Zhong F, Distelhorst CW (2006) Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene 25:1903–1913PubMedCrossRef
33.
Avram D, Ranta F, Hennige AM et al (2008) IGF-1 protects against dexamethasone-induced cell death in insulin secreting INS-1 cells independent of AKT/PKB phosphorylation. Cell Physiol Biochem 21:455–462PubMedCrossRef
34.
Davani B, Portwood N, Bryzgalova G et al (2004) Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes 53(Suppl 1):S51–S59PubMedCrossRef
35.
Billaudel B, Mathias PC, Sutter BC, Malaisse WJ (1984) Inhibition by corticosterone of calcium inflow and insulin release in rat pancreatic islets. J Endocrinol 100:227–233PubMedCrossRef
36.
Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29:119–121PubMedCrossRef
37.
Gremlich S, Roduit R, Thorens B (1997) Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 272:3216–3222PubMedCrossRef
38.
Ullrich S, Berchtold S, Ranta F et al (2005) Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 54:1090–1099PubMedCrossRef
39.
Zhang X, Yong W, Lv J et al (2009) Inhibition of forkhead box O1 protects pancreatic beta-cells against dexamethasone-induced dysfunction. Endocrinology 150:4065–4073PubMedCrossRef
40.
Shalev A, Pise-Masison CA, Radonovich M et al (2002) Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 143:3695–3698PubMedCrossRef
41.
Rani S, Mehta JP, Barron N et al (2010) Decreasing Txnip mRNA and protein levels in pancreatic MIN6 cells reduces reactive oxygen species and restores glucose regulated insulin secretion. Cell Physiol Biochem 25:667–674PubMedCrossRef
42.
Hotta M, Tashiro F, Ikegami H et al (1998) Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 188:1445–1451PubMedCrossRef
43.
Yamamoto M, Yamato E, Toyoda S et al (2008) Transgenic expression of antioxidant protein thioredoxin in pancreatic beta cells prevents progression of type 2 diabetes mellitus. Antioxid Redox Signal 10:43–49PubMedCrossRef
44.
Nishiyama A, Matsui M, Iwata S et al (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274:21645–21650PubMedCrossRef
45.
Butler LM, Zhou X, Xu WS et al (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700–11705PubMedCrossRef
46.
Oka S, Masutani H, Liu W et al (2006) Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology 147:733–743PubMedCrossRef
47.
Shao J, Qiao L, Friedman JE (2004) Prolactin, progesterone, and dexamethasone coordinately and adversely regulate glucokinase and cAMP/PDE cascades in MIN6 beta-cells. Am J Physiol 286:E304–E310CrossRef
48.
Shao W, Yu Z, Fantus IG, Jin T (2010) Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells. Cell Signal 22:1240–1246PubMedCrossRef
49.
Li X, Rong Y, Zhang M et al (2009) Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun 381:660–665PubMedCrossRef
50.
Ren Y, Shi Y, Wang Y et al (2010) p38 MAPK pathway is involved in high glucose-induced thioredoxin interacting protein induction in mouse mesangial cells. FEBS Lett 584:3480–3485PubMedCrossRef
51.
Zanchi NE, Filho MA, Felitti V, Nicastro H, Lorenzeti FM, Lancha AH Jr (2010) Glucocorticoids: extensive physiological actions modulated through multiple mechanisms of gene regulation. J Cell Physiol 224:311–315PubMedCrossRef
Metadata
Title
Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death
Authors
E. Reich
A. Tamary
R. Vogt Sionov
D. Melloul
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2422-z

Other articles of this Issue 4/2012

Diabetologia 4/2012 Go to the issue

Article

Mesenchymal stem cells differentially mediate regulatory T cells and conventional effector T cells to protect fully allogeneic islet grafts in mice

Article

Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians

Article

Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes

Article

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

Article

Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans

Article

The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits